Founded in 1849, the corporation has its headquarters in New York City, New York, United States, and is recognized for its diverse portfolio in the biopharmaceutical sector. Among the critical areas of focus are internal medicine, oncology, vaccine development, inflammation and immunology, rare diseases, and hospital products, which constitute vital components of their operations.
Within the biopharmaceutical segment, vaccines are a significant area of emphasis. A prominent example is the COVID-19 vaccine, developed in collaboration with BioNTech. The oncology division has also established a robust presence in the cancer treatment market with a suite of therapy options for various types of cancer.
Historically, the consumer healthcare segment was part of the business until it transitioned into a joint venture with GlaxoSmithKline, forming GSK Consumer Healthcare. However, this part of the company has since been spun off into an independent entity known as Haleon.
Prominent brands from this corporation include the Prevnar family, known for pneumococcal vaccines; Ibrance (palbociclib), a cancer treatment; Eliquis (apixaban), an anticoagulant; Vyndaqel/Vyndamax (tafamidis), for treating the rare disease ATTR-CM; Xeljanz (tofacitinib), aimed at certain autoimmune conditions; and the smoking cessation aid Chantix (varenicline), although Chantix was sold to Haleon. Additionally, the BNT162b2 vaccine, branded as Comirnaty, constitutes a landmark development in the fight against the global COVID-19 pandemic.
Globally, this corporation's products and services are available in over 125 countries, with significant markets in the United States, China, Japan, Germany, France, Italy, Spain, the United Kingdom, Canada, and Brazil. These countries are indicative of the corporation's extensive reach and importance on a global scale. (Powered by AI)